BioSpace News Archive

Harrow today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia.

NeoGenomics, Inc. announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms.

BioSig Technologies, Inc. confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB.

Gracell Biotechnologies Inc. today reported fourth quarter and full year 2022 unaudited financial results for the period ended December 31, 2022, and provided corporate updates.

On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines.

DBV Technologies, a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.

Royal Philips, a global leader in health technology, announced the appointment of Julia Strandberg as the Chief Business Leader of its Connected Care businesses, effective April 24, 2023.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, informed its shareholders that BioInvent does not hold cash deposits or securities at Silicon Valley Bank, or any other foreign bank.

Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase 1 clinical study evaluating BAT8007, an antibody-drug conjugate that targets Nectin-4.

AlzeCure Pharma AB announced that the Last Patient Last Visit has now been completed in the ongoing phase II clinical trial with ACD440, the lead non-opioid drug candidate in the Painless platform, which is being developed against peripheral neuropathic pain.